It has been suggested that these compounds act as central inhibitors of inflammatory and immune responses in experimental colitis via the inhibition of NF-κB activation, reduction of pro-inflammatory cytokines production and down-regulation of Th1 and Th17 immune responses [17,56,57,58]. Here, NFKB1 is linked to colitis.